A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
Trial details
- Registry ID
- NCT05975060
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.NCT05975060 | Novavax | Phase 2, Phase 3 | Completed | 2023-11-15Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |